ArticleMolecular oncology2024

FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling.

Marion Morel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.